Skip to main content

Table 3 Potentially ASAQ-related adverse events

From: Safety of a fixed-dose combination of artesunate and amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in real-life conditions of use in Côte d’Ivoire

  Number of adverse events Number of episodes Incidencea
Any potentially ASAQ-related adverse event 929 837 5.5%
Asthenia 410 410 2.7
Somnolence 134 134 0.9
Vomiting 89 89 0.6
Dizziness 84 84 0.6
Diarrhoea 21 21 0.1
Insomnia 13 13 0.1
Abdominal pain 12 12 0.1
Pruritus 26 26 0.2
Decreased appetite 28 28 0.2
Cough 13 13 0.1
  1. Only individual adverse events reported during more than ten malaria episodes are listed in this table
  2. aCalculated with respect to the 15,228 documented malaria episodes